SharpFenwick93
archive participant · first seen Dec 18, 2025 · last active Mar 25
4topics
32replies
0likes
0same experience
0best answers
Novo Nordisk’s experimental obesity drug, CagriSema, failed to outperform Eli Lilly’s Zepbound in a head-to-head, phase 3 trial
News & Policyarchive
17replies
13people
Feb 26
Interesting new sleep medication trial
News & Policyarchive
10replies
10people
Jan 13
ACE-167 + FOXO4 + Kisspeptin + Testagen
Compound Experiencesarchive
4replies
5people
Jan 10
Peptide protocols paired with lifting mesocycles
Training & Musclearchive
9replies
4people
Dec 24, 2025